Chronic lung disease of the neonate; Pathophysiology and treatment after the first weeks of life;Chronische longziekte van de pasgeborene; Pathofysiologie en behandeling na de eerste levensweken

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 49, 2003, Pages 2412-2417

  Vrijlandt, E J L E ^a   Duiverman, E J ^a   Bos, A F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIURETIC AGENT; FLUTICASONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SALBUTAMOL; SPIRONOLACTONE;

ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CANDIDIASIS; CHRONIC LUNG DISEASE; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DIURETIC THERAPY; FLUID RETENTION; FLUID THERAPY; HUMAN; HYPERCALCIURIA; HYPERCAPNIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOXEMIA; INFLUENZA; LUNG FUNCTION TEST; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; OXYGEN THERAPY; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA; VACCINATION;

CHRONIC DISEASE; FAILURE TO THRIVE; HUMANS; INFANT, NEWBORN; LUNG DISEASES; OXYGEN INHALATION THERAPY; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RISK FACTORS;

EID: 0345059726     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Northway jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68.
2. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82:527-32.
3. Bancalari E, Gonzalez A. Clinical course and lung function abnormalities during development of neonatal chronic lung disease. In: Bland RD, Coalson JJ, editors. Chronic lung disease in early infancy. New York: Marcel Dekker; 2000. p. 41-64.
4. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641-3.
5. Coalson JJ. Pathology of chronic lung disease of early infancy. In: Bland RD, Coalson JJ, editors. Chronic lung disease in early infancy. New York: Marcel Dekker; 2000. p. 85-124.
6. Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, Yoder BA. Lung injury in neonates: causes, strategies for prevention and long-term consequences. J Pediatr 2001;139:478-86.
7. Northway jr WH, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990;323:1793-9.
8. Duiverman EJ, Boer JA den, Roorda RJ, Rooyackers CM, Valstar M, Kerrebijn KF, et al. Lung function and bronchial responsiveness measured by forced oscillometry after bronchopulmonary dysplasia. Arch Dis Child 1988;63:727-32.
9. Hakulinen AL, Heinonen K, Lansimies E, Kiekara O. Pulmonary function and respiratory morbidity in school-age children born prematurely and ventilated for neonatal respiratory insufficiency. Pediatr Pulmonol 1990;8:226-32.
10. Hakulinen AL, Jarvenpaa AL, Turpeinen M, Sovijarvi A. Diffusing capacity of the lung in school-aged children born very preterm, with and without bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21:353-60.
11. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants [Cochrane review]. The Cochrane Library. Issue I. Oxford: Update Software; 2003.
12. Huysman WA, Ridder M de, Bruin NC de, Helmond G van, Terpstra N, Goudoever JB van, et al. Growth and body composition in preterm infants with bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 2003;88:F46-51.
13. Brunton JA, Saigal S, Atkinson SA. Growth and body composition in infants with bronchopulmonary dysplasia up to 3 months corrected age: a randomized trial of a high-energy nutrient-enriched formula fed after hospital discharge. J Pediatr 1998;133:340-5.
14. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease [Cochrane review]. The Cochrane Library. Issue I. Oxford: Update Software; 2002.
15. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease [Cochrane review]. The Cochrane Library. Issue I. Oxford: Update Software; 2002.
16. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants [Cochrane review]. The Cochrane Library. Issue I. Oxford: Update Software; 2003.
17. Lister P, Iles R, Shaw B, Ducharme F. Inhaled steroids for neonatal chronic lung disease [Cochrane review]. The Cochrane Library. Issue 3. Oxford: Update Software; 2000.
18. Fok TF, Lam K, Ng PC, Leung TF, So HK, Cheung KL, et al. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 1998;12:159-64.
19. Fok TF, Lam K, Ng PC, So HK, Cheung KL, Wong W, et al. Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998;79:F100-4.
20. Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants [Cochrane review]. The Cochrane Library. Issue 3. Oxford: Update Software; 2001.
21. Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1990;142:1137-42.